Bronstein, Gewirtz and Grossman, LLC Announces an Investigation Against Syros Pharmaceuticals, Inc. (SYRS) and Encourages Investors to Seek Compensation for Alleged Wrongdoings
Bronstein, Gewirtz and Grossman, is investigating potential claims against Syros Pharmaceuticals, Inc. (NASDAQ:SYRS). The investigation follows Syros' announcement on August 12, 2024, that it will discontinue enrollment in the SELECT-AML-1 Phase 2 clinical trial for acute myeloid leukemia (AML) treatment. This decision was based on a prespecified interim analysis indicating a low probability of demonstrating superiority at the final analysis. Investors who purchased Syros securities are encouraged to participate in the investigation. The law firm is offering its services on a contingency fee basis, seeking reimbursement for expenses and attorneys' fees only if successful.
Bronstein, Gewirtz e Grossman stanno indagando su potenziali azioni legali contro Syros Pharmaceuticals, Inc. (NASDAQ:SYRS). L'indagine segue l'annuncio di Syros del 12 agosto 2024, secondo cui interromperà l'arruolamento nello studio clinico di fase 2 SELECT-AML-1 per il trattamento della leucemia mieloide acuta (LMA). Questa decisione è stata presa sulla base di un'analisi intermedia prestabilita che indicava una bassa probabilità di dimostrare superiorità nell'analisi finale. Gli investitori che hanno acquistato titoli Syros sono incoraggiati a partecipare all'indagine. Lo studio legale offre i suoi servizi su base di onorari condizionali, cercando il rimborso delle spese e degli onorari solo in caso di successo.
Bronstein, Gewirtz y Grossman están investigando posibles reclamaciones contra Syros Pharmaceuticals, Inc. (NASDAQ:SYRS). La investigación sigue al anuncio de Syros del 12 de agosto de 2024, de que discontinuará la inscripción en el ensayo clínico de fase 2 SELECT-AML-1 para el tratamiento de la leucemia mieloide aguda (LMA). Esta decisión se basó en un análisis intermedio preestablecido que indicaba una baja probabilidad de demostrar superioridad en el análisis final. Se alienta a los inversores que compraron valores de Syros a participar en la investigación. La firma legal ofrece sus servicios con una tarifa de contingencia, buscando el reembolso de gastos y honorarios de abogados solo si tienen éxito.
브론스타인, 게위르츠, 그리고 그로스만은 시로스 제약 주식회사(NASDAQ:SYRS)에 대한 잠재적 청구를 조사하고 있습니다. 이 조사는 시로스가 2024년 8월 12일에 SELECT-AML-1 2상 임상 시험 등록을 중단하겠다고 발표한 데 따른 것입니다. 이 결정은 최종 분석에서 우월성을 입증할 확률이 낮다고 나타난 사전 지정된 중간 분석에 기초했습니다. 시로스 증권을 구매한 투자자들은 조사에 참여할 것을 권장합니다. 법무법인은 성공 시에만 비용 및 변호사 수수료에 대한 환급을 찾는 조건부 수수료 기반으로 서비스를 제공하고 있습니다.
Bronstein, Gewirtz et Grossman mènent une enquête sur d'éventuelles réclamations contre Syros Pharmaceuticals, Inc. (NASDAQ:SYRS). L'enquête fait suite à l'annonce de Syros du 12 août 2024, selon laquelle l'inscription à l'essai clinique de phase 2 SELECT-AML-1 pour le traitement de la leucémie myéloïde aiguë (LMA) sera interrompue. Cette décision a été motivée par une analyse intermédiaire prédéfinie indiquant une faible probabilité de démontrer la supériorité lors de l'analyse finale. Les investisseurs ayant acheté des titres Syros sont encouragés à participer à l'enquête. Le cabinet d'avocats propose ses services sur une base de frais conditionnels, recherchant un remboursement des frais et des honoraires d'avocat uniquement en cas de succès.
Bronstein, Gewirtz und Grossman untersuchen potenzielle Ansprüche gegen Syros Pharmaceuticals, Inc. (NASDAQ:SYRS). Die Untersuchung folgt auf die Ankündigung von Syros am 12. August 2024, dass die Einschreibung in die SELECT-AML-1 Phase-2-Studie zur Behandlung von akuter myeloischer Leukämie (AML) eingestellt wird. Diese Entscheidung beruhte auf einer vordefinierten Zwischenanalyse, die eine geringe Wahrscheinlichkeit für die Demonstration der Überlegenheit bei der finalen Analyse anzeigte. Investoren, die Syros-Wertpapiere erworben haben, werden ermutigt, an den Ermittlungen teilzunehmen. Die Kanzlei bietet ihre Dienstleistungen auf Erfolgsbasis an und strebt eine Erstattung von Kosten und Anwaltsgebühren nur im Erfolgsfall an.
- None.
- Discontinuation of SELECT-AML-1 Phase 2 clinical trial enrollment
- Low probability of demonstrating treatment superiority in AML therapy
- Potential legal claims against the company
- Possible negative impact on investor confidence and stock value
This investigation into Syros Pharmaceuticals raises significant legal and financial concerns. The discontinuation of the SELECT-AML-1 Phase 2 clinical trial due to low probability of success is a material event that could potentially impact shareholder value. The law firm's involvement suggests possible securities fraud allegations, which could lead to class action lawsuits.
Investors should be aware that such investigations often precede formal legal actions. If wrongdoing is found, it could result in financial penalties and reputational damage for Syros. However, it's important to note that at this stage, these are merely allegations and no wrongdoing has been proven. The investigation's outcome will depend on the evidence gathered and could have long-term implications for the company's governance and investor relations.
The discontinuation of the SELECT-AML-1 Phase 2 clinical trial is a significant setback for Syros Pharmaceuticals. This trial was testing a novel triplet regimen for acute myeloid leukemia (AML), a challenging cancer to treat. The decision to halt enrollment based on interim analysis suggests that the treatment's efficacy did not meet expectations.
This outcome could have far-reaching implications for Syros's pipeline and strategy in AML treatment. It may necessitate a reevaluation of their approach to RARA gene overexpression in AML. However, it's important to note that clinical trial failures are not uncommon in oncology drug development. The company's decision to discontinue based on data analysis demonstrates a commitment to efficient resource allocation and ethical trial conduct.
This news is likely to have a negative impact on Syros Pharmaceuticals' stock price and investor confidence. The discontinuation of a Phase 2 trial represents a significant setback in the company's drug development pipeline, potentially affecting future revenue projections and market position in the competitive oncology sector.
Investors should closely monitor the company's cash burn rate and pipeline diversity. The failure of this trial may lead to increased scrutiny of Syros's other ongoing research programs. Additionally, the legal investigation could result in increased legal expenses and potential liabilities. These factors combined may impact the company's financial stability and ability to raise capital in the short to medium term, making it important for investors to reassess their risk tolerance and investment thesis for Syros.
NEW YORK CITY, NY / ACCESSWIRE / August 26, 2024 / Bronstein, Gewirtz & Grossman, LLC is investigating potential claims on behalf of purchasers of Syros Pharmaceuticals, Inc. ("Syros" or "the Company") (NASDAQ:SYRS). Investors who purchased Syros securities are encouraged to obtain additional information and assist the investigation by visiting the firm's site: bgandg.com/SYRS.
Investigation Details
On August 12, 2024, Syros issued a press release "announcing that it will discontinue enrollment in the SELECT-AML-1 Phase 2 clinical trial evaluating the triplet regimen of tamibarotene in combination with venetoclax and azacitidine compared to the doublet regimen of venetoclax and azacitidine in newly diagnosed, unfit patients with acute myeloid leukemia (AML) and RARA gene overexpression." According to the Company, the "decision is based on the results of a prespecified interim analysis of the trial," and its analysis that "the probability for success . . . to demonstrate superiority at the final analysis . . . was considered low."
What's Next?
If you are aware of any facts relating to this investigation or purchased Syros securities, you can assist this investigation by visiting the firm's site: bgandg.com/SYRS. You can also contact Peretz Bronstein or his client relations manager, Nathan Miller, of Bronstein, Gewirtz & Grossman, LLC: 332-239-2660.
There is No Cost to You
We represent investors in class actions on a contingency fee basis. That means we will ask the court to reimburse us for out-of-pocket expenses and attorneys' fees, usually a percentage of the total recovery, only if we are successful.
Why Bronstein, Gewirtz & Grossman
Bronstein, Gewirtz & Grossman, LLC is a nationally recognized firm that represents investors in securities fraud class actions and shareholder derivative suits. Our firm has recovered hundreds of millions of dollars for investors nationwide.
Attorney advertising. Prior results do not guarantee similar outcomes.
CONTACT:
Bronstein, Gewirtz & Grossman, LLC
Peretz Bronstein or Nathan Miller,
332-239-2660 | info@bgandg.com
SOURCE: Bronstein, Gewirtz and Grossman, LLC
View the original press release on accesswire.com
FAQ
Why is Syros Pharmaceuticals (SYRS) under investigation?
What was the outcome of Syros Pharmaceuticals' (SYRS) SELECT-AML-1 Phase 2 clinical trial?
How can investors participate in the investigation against Syros Pharmaceuticals (SYRS)?
What are the potential consequences for Syros Pharmaceuticals (SYRS) following this investigation?
